Zobrazit v EDS

European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

Uloženo v:
Podrobná bibliografie
Název: European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs
Autoři: Susana Otero‐Romero, Christine Lebrun‐Frénay, Saúl Reyes, Maria Pia Amato, Magda Campins, Mauricio Farez, Massimo Filippi, Yael Hacohen, Bernhard Hemmer, Rosa Juuti, Melinda Magyari, Celia Oreja‐Guevara, Aksel Siva, Sandra Vukusic, Mar Tintoré
Přispěvatelé: Institut Català de la Salut, [Otero-Romero S] Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Lebrun-Frénay C] CRCSEP Nice, CHU de Nice Pasteur, Universite ́ Nice Cote d’Azur UR2CA-URRIS, Nice, France. [Reyes S] Fundación Santa Fe de Bogotá, Bogotá, Colombia. School of Medicine, Universidad de los Andes, Bogotá, Colombia. Barts and The London School of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK. [Amato MP] Department NEUROFARBA, University of Florence, Florence, Italy. IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy. [Campins M] Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Farez M] Centro para la Investigación de Enfermedades Neuroinmunológicas (CIEN), FLENI, Buenos Aires, Argentina. [Tintoré M] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, İstanbul University Cerrahpaşa Institutional Repository
Zdroj: Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Otero-Romero, S, Lebrun-Frénay, C, Reyes, S, Amato, M P, Campins, M, Farez, M, Filippi, M, Hacohen, Y, Hemmer, B, Juuti, R, Magyari, M, Oreja-Guevara, C, Siva, A, Vukusic, S & Tintoré, M 2023, ' European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis : Improving immunization strategies in the era of highly active immunotherapeutic drugs ', European Journal of Neurology, vol. 30, no. 8, pp. 2144-2176 . https://doi.org/10.1111/ene.15809
Informace o vydavateli: Wiley, 2023.
Rok vydání: 2023
Témata: TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunoterapia activa::vacunación, Multiple Sclerosis, Consensus, Human-Papillomavirus Vaccine, Decisió de grup, Other subheadings::Other subheadings::/therapy, Ms, Recommendations, multiple sclerosis, DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis, Pregnancy, Influenza Vaccination, Humans, PSIQUIATRÍA Y PSICOLOGÍA::conducta y mecanismos de la conducta::psicología social::procesos de grupo::consenso, infections, Relapse, Child, PSYCHIATRY AND PSYCHOLOGY::Behavior and Behavior Mechanisms::Psychology, Social::Group Processes::Consensus, Aged, Immune-Response, Vaccination, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunotherapy, Active::Vaccination, consensus, disease-modifying therapy, vaccination, Bacille-Calmette-Guerin, 3. Good health, Otros calificadores::Otros calificadores::/terapia, ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple, Neurology, Controlled-Trial, Antibody-Response, Interferon, Female, Immunization, Esclerosi múltiple - Vacunació
Popis: Background and purposeWith the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategy. We aimed to develop a European evidence‐based consensus for the vaccination strategy of pwMS who are candidates for disease‐modifying therapies (DMTs).MethodsThis work was conducted by a multidisciplinary working group using formal consensus methodology. Clinical questions (defined as population, interventions and outcomes) considered all authorized DMTs and vaccines. A systematic literature search was conducted and quality of evidence was defined according to the Oxford Centre for Evidence‐Based Medicine Levels of Evidence. The recommendations were formulated based on the quality of evidence and the risk–benefit balance.ResultsSeven questions, encompassing vaccine safety, vaccine effectiveness, global vaccination strategy and vaccination in subpopulations (pediatric, pregnant women, elderly and international travelers) were considered. A narrative description of the evidence considering published studies, guidelines and position statements is presented. A total of 53 recommendations were agreed by the working group after three rounds of consensus.ConclusionThis first European consensus on vaccination in pwMS proposes the best vaccination strategy according to current evidence and expert knowledge, with the goal of homogenizing the immunization practices in pwMS.
Druh dokumentu: Article
Popis souboru: application/pdf
Jazyk: English
ISSN: 1468-1331
1351-5101
DOI: 10.1111/ene.15809
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/37293849
https://hdl.handle.net/11351/10041
https://hdl.handle.net/20.500.11768/143557
https://onlinelibrary.wiley.com/doi/10.1111/ene.15809
https://doi.org/10.1111/ene.15809
https://curis.ku.dk/ws/files/367470609/Euro_J_of_Neurology_2023_Otero_Romero.pdf
https://hdl.handle.net/2158/1356556
https://doi.org/10.1111/ene.15809
https://epub.ub.uni-muenchen.de/117329/
Rights: CC BY NC ND
Přístupové číslo: edsair.doi.dedup.....b7a7326987f5713a88ea14598c6fb8e2
Databáze: OpenAIRE
Popis
Abstrakt:Background and purposeWith the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategy. We aimed to develop a European evidence‐based consensus for the vaccination strategy of pwMS who are candidates for disease‐modifying therapies (DMTs).MethodsThis work was conducted by a multidisciplinary working group using formal consensus methodology. Clinical questions (defined as population, interventions and outcomes) considered all authorized DMTs and vaccines. A systematic literature search was conducted and quality of evidence was defined according to the Oxford Centre for Evidence‐Based Medicine Levels of Evidence. The recommendations were formulated based on the quality of evidence and the risk–benefit balance.ResultsSeven questions, encompassing vaccine safety, vaccine effectiveness, global vaccination strategy and vaccination in subpopulations (pediatric, pregnant women, elderly and international travelers) were considered. A narrative description of the evidence considering published studies, guidelines and position statements is presented. A total of 53 recommendations were agreed by the working group after three rounds of consensus.ConclusionThis first European consensus on vaccination in pwMS proposes the best vaccination strategy according to current evidence and expert knowledge, with the goal of homogenizing the immunization practices in pwMS.
ISSN:14681331
13515101
DOI:10.1111/ene.15809